FiftyBidsGovernment contracts and grants, sent to your inbox.

Back to search

Open grant

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb).

FromNational Institutes of Health
Who can applystate governments, counties, cities and townships, special districts (water, fire, parks, etc.), school districts, public colleges and universities and 9 more types
Eligibility notesRefer to Section III.
How muchabout 4 awards; $40 million total
DeadlineTue, Nov 10, 2026 (18 days left)
CategoryHealth
TypeCooperative agreement
Opportunity #RFA-NS-26-001
Assistance listing93.853
PostedMon, May 4, 2026

Open the official posting

From the notice

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.

We may have shortened this. The official posting is the record. We are not affiliated with the agency that published it.